Financial Report: Johnson & Johnson 3Q

Johnson & Johnson 3Q

3Q Revenues: $15.0 billion (-1%)

3Q Earnings: $3.4 billion (+2%)

YTD Revenue: $45.9 billion (+1%)

YTD Earnings: $11.4 billion (+13%)

Comments: Worldwide Pharmaceutical sales were $5.5 billion in the quarter (+5%), with operational growth of 6% and a negative impact from currency of 1%. Domestic and international sales were up 7% and 2%, respectively. Remicade sales were $1.2 billion in the quarter (+19%). Prezista sales were $230 million (+52%). Risperdal Consta sales were $378 million (+7%). Velcade sales were up 7% to $246 million. Procrit sales dropped 25% to $406 million. Risperdal sales were down 37% to $121 million. Topamax sales were down 27% to $127 million. Worldwide Consumer sales dropped 11% in the quarter to $3.6 billion, taking a hit from OTC product recalls including Tylenol and Motrin, along with the closure of a factory. Worldwide Medical Devices and Diagnostics sales were $5.9 billion (+1%).